Premium
Amyloid‐β induces sleep fragmentation that is rescued by fatty acid binding proteins in Drosophila
Author(s) -
Gerstner Jason R.,
Lenz Olivia,
Vanderheyden William M.,
Chan May T.,
Pfeiffenberger Cory,
Pack Allan I.
Publication year - 2017
Publication title -
journal of neuroscience research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.72
H-Index - 160
eISSN - 1097-4547
pISSN - 0360-4012
DOI - 10.1002/jnr.23778
Subject(s) - sleep (system call) , transgene , wakefulness , sleep deprivation , biology , genetically modified mouse , amyloid precursor protein , neuroscience , endocrinology , microbiology and biotechnology , medicine , alzheimer's disease , disease , circadian rhythm , biochemistry , gene , electroencephalography , computer science , operating system
Disruption of sleep/wake activity in Alzheimer's disease (AD) patients significantly affects their quality of life and that of their caretakers and is a major contributing factor for institutionalization. Levels of amyloid‐β (Aβ) have been shown to be regulated by neuronal activity and to correlate with the sleep/wake cycle. Whether consolidated sleep can be disrupted by Aβ alone is not well understood. We hypothesize that Aβ42 can increase wakefulness and disrupt consolidated sleep. Here we report that flies expressing the human Aβ42 transgene in neurons have significantly reduced consolidated sleep compared with control flies. Fatty acid binding proteins (Fabp) are small hydrophobic ligand carriers that have been clinically implicated in AD. Aβ42 flies that carry a transgene of either the Drosophila Fabp or the mammalian brain‐type Fabp show a significant increase in nighttime sleep and long consolidated sleep bouts, rescuing the Aβ42‐induced sleep disruption. These studies suggest that alterations in Fabp levels and/or activity may be associated with sleep disturbances in AD. Future work to determine the molecular mechanisms that contribute to Fabp‐mediated rescue of Aβ42‐induced sleep loss will be important for the development of therapeutics in the treatment of AD. © 2016 Wiley Periodicals, Inc.